Myers Scott Dunseth
Chief Executive Officer at VRDN
- Sold, on record
- None
- Dollars the filings state
- Form 4 sales
- 0
- None on record
- Form 144 notices
- 1
- Proposed sales
- Quarters with a sale
- 0 of the last 8
- No sale in two years
- Companies
- 1
- Filed as an executive or holder
Companies
- VRDNViridian Therapeutics, Inc.\DEChief Executive Officer
Sales by reason
No Form 4 sale on record for Myers Scott Dunseth.
Timeline
- Nov 16, 2023Notice
Filed a notice to sell 35,368 shares
$535k35,368 shares
1 of 1
Every transaction
| Traded | Filed | Stock | Role | What | Amount | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Jun 18, 2026 | ZNTL | Director | Awarded | 57,100 | 395,895 | SEC | ||
| Feb 10, 2026 | Feb 10, 2026 | DYNAVAX TECHNOLOGIES CORP | Director | Tendered | 3,800 | 0 | SEC | ||
| Feb 10, 2026 | Feb 10, 2026 | DYNAVAX TECHNOLOGIES CORP | Director | Returned to the companyStock Option (Right to Buy) | 135,375 | 0 | SEC | ||
| Feb 10, 2026 | Feb 10, 2026 | DYNAVAX TECHNOLOGIES CORP | Director | Returned to the company | 31,204 | 0 | SEC | ||
| Aug 22, 2025 | Aug 25, 2025 | DYNAVAX TECHNOLOGIES CORP | Director | Bought | 3,800 | $10.82 | $41k | 35,004 | SEC |
| Jun 17, 2025 | Jun 18, 2025 | ZNTL | Director | Awarded | 57,603 | 338,795 | SEC | ||
| Jun 11, 2025 | Jun 13, 2025 | DYNAVAX TECHNOLOGIES CORP | Director | AwardedStock Option (Right to Buy) | 28,500 | 28,500 | SEC | ||
| Jun 11, 2025 | Jun 13, 2025 | DYNAVAX TECHNOLOGIES CORP | Director | Awarded | 5,758 | 31,204 | SEC | ||
| Apr 30, 2025 | Apr 30, 2025 | ZNTL | Director | Bought | 21,000 | $1.40 | $29k | 281,192 | SEC |
| Nov 13, 2024 | Nov 13, 2024 | ZNTL | Director | Awarded | 260,192 | 260,192 | SEC | ||
| May 23, 2024 | May 28, 2024 | DYNAVAX TECHNOLOGIES CORP | Director | AwardedStock Option (Right to Buy) | 22,500 | 22,500 | SEC | ||
| May 23, 2024 | May 28, 2024 | DYNAVAX TECHNOLOGIES CORP | Director | Awarded | 5,357 | 25,446 | SEC | ||
| Mar 11, 2024 | Mar 11, 2024 | Harpoon Therapeutics, Inc. | Director | Returned to the companyDirector Stock Option (Right to Buy) | 6,633 | 0 | SEC | ||
| Mar 11, 2024 | Mar 11, 2024 | Harpoon Therapeutics, Inc. | Director | Returned to the company | 22,665 | 0 | SEC | ||
| Jan 1, 2024 | Jan 3, 2024 | Harpoon Therapeutics, Inc. | Director | Awarded | 2,048 | 22,666 | SEC | ||
| Nov 27, 2023 | Nov 28, 2023 | Harpoon Therapeutics, Inc. | Director | Awarded | 5,000 | 20,618 | SEC | ||
| Nov 13, 2023 | Nov 15, 2023 | RNAC | Director | Returned to the companyStock Option (Right to Buy) | 207,500 | $0.39 | $81k | 0 | SEC |
| Oct 1, 2023 | Oct 2, 2023 | Harpoon Therapeutics, Inc. | Director | Awarded | 5,797 | 15,618 | SEC | ||
| Jul 1, 2023 | Jul 6, 2023 | Harpoon Therapeutics, Inc. | Director | Awarded | 35,634 | 98,215 | SEC | ||
| Jun 22, 2023 | Jun 23, 2023 | Harpoon Therapeutics, Inc. | Director | AwardedDirector Stock Option (Right to Buy) | 46,000 | 46,000 | SEC | ||
| May 26, 2023 | May 31, 2023 | DYNAVAX TECHNOLOGIES CORP | Director | AwardedStock Option (Right to Buy) | 22,500 | 22,500 | SEC | ||
| May 26, 2023 | May 31, 2023 | DYNAVAX TECHNOLOGIES CORP | Director | Awarded | 5,357 | 20,089 | SEC | ||
| Apr 12, 2023 | Apr 12, 2023 | VRDN | Chief Executive Officer | Bought | 4,000 | $25.37 | $101k | 259,500 | SEC |
| Apr 1, 2023 | Apr 4, 2023 | Harpoon Therapeutics, Inc. | Director | Awarded | 34,925 | 62,581 | SEC | ||
| Mar 13, 2023 | Mar 13, 2023 | VRDN | Chief Executive Officer | Bought | 5,500 | $29.15 | $160k | 255,500 | SEC |
| Feb 6, 2023 | Feb 7, 2023 | VRDN | Chief Executive Officer | AwardedStock Option (Right to Buy) | 1M | 1M | SEC | ||
| Feb 6, 2023 | Feb 7, 2023 | VRDN | Chief Executive Officer | Awarded | 250,000 | 250,000 | SEC | ||
| Jan 2, 2023 | Jan 4, 2023 | RNAC | Director | AwardedStock Option (Right to Buy) | 87,500 | 87,500 | SEC | ||
| Jun 22, 2022 | Jun 24, 2022 | Harpoon Therapeutics, Inc. | Director | AwardedDirector Stock Option (Right to Buy) | 20,334 | 20,334 | SEC | ||
| May 26, 2022 | May 27, 2022 | DYNAVAX TECHNOLOGIES CORP | Director | AwardedRestricted Stock Unit | 20,893 | 16,875 | SEC | ||
| Jan 3, 2022 | Jan 5, 2022 | RNAC | Director | AwardedStock Option (Right to Buy) | 40,000 | 40,000 | SEC | ||
| Nov 17, 2021 | Nov 19, 2021 | Trillium Therapeutics Inc. | Director | Returned to the companyStock Option (Right to Buy) | 67,000 | 0 | SEC | ||
| Oct 25, 2021 | Oct 26, 2021 | Harpoon Therapeutics, Inc. | Director | AwardedDirector Stock Option (Right to Buy) | 10,167 | 10,167 | SEC | ||
| Oct 19, 2021 | Oct 21, 2021 | DYNAVAX TECHNOLOGIES CORP | Director | AwardedRestricted Stock Unit | 55,714 | 45,000 | SEC | ||
| May 4, 2021 | May 7, 2021 | Harpoon Therapeutics, Inc. | Director | AwardedDirector Stock Option (Right to Buy) | 10,167 | 10,167 | SEC | ||
| May 3, 2021 | May 5, 2021 | Trillium Therapeutics Inc. | Director | AwardedStock Option (Right to Buy) | 67,000 | 67,000 | SEC | ||
| Mar 30, 2021 | Apr 1, 2021 | RNAC | Director | AwardedStock Option (Right to Buy) | 40,000 | 40,000 | SEC | ||
| Nov 16, 2020 | Nov 17, 2020 | ADVANCED MAGNETICS INC | President & CEO | Returned to the companyStock Option (Right to Buy) | 1M | 0 | SEC | ||
| Jun 19, 2020 | Jun 23, 2020 | RNAC | Director | AwardedStock Option (Right to Buy) | 20,000 | 20,000 | SEC | ||
| May 28, 2020 | Jun 1, 2020 | Harpoon Therapeutics, Inc. | Director | AwardedDirector Stock Option (Right to Buy) | 10,167 | 10,167 | SEC | ||
| Apr 28, 2020 | Apr 30, 2020 | ADVANCED MAGNETICS INC | President & CEO | AwardedStock Option (Right to Buy) | 1M | 1M | SEC | ||
| Dec 23, 2019 | Dec 26, 2019 | RNAC | Director | AwardedWarrants | 19,704 | $0.13 | $3k | 19,704 | SEC |
| Dec 23, 2019 | Dec 26, 2019 | RNAC | Director | Awarded | 39,409 | $1.46 | $58k | 80,845 | SEC |
| Aug 20, 2019 | Aug 20, 2019 | RNAC | Director | Awarded | 41,436 | $1.81 | $75k | 41,436 | SEC |
| Jun 14, 2019 | Jun 18, 2019 | RNAC | Director | AwardedStock Option (Right to Buy) | 20,000 | 20,000 | SEC | ||
| Jun 3, 2019 | Jun 5, 2019 | Harpoon Therapeutics, Inc. | Director | AwardedDirector Stock Option (Right to Buy) | 10,167 | 10,167 | SEC | ||
| Mar 9, 2018 | Mar 13, 2018 | Oncothyreon Inc. | President and CEO | Tendered | 56,787 | 0 | SEC | ||
| Mar 9, 2018 | Mar 13, 2018 | Oncothyreon Inc. | President and CEO | Returned to the companyStock Option (Right to buy) | 1M | 0 | SEC | ||
| Feb 1, 2018 | Feb 2, 2018 | Oncothyreon Inc. | President and CEO | AwardedRestricted Share Unit (RSU) | 250,000 | 250,000 | SEC | ||
| Jan 11, 2018 | Jan 16, 2018 | Oncothyreon Inc. | President and CEO | Exercised or settledRestricted Share Unit (RSU) | 10,500 | 31,500 | SEC |
Page 1